Celltrion Completes Application For FDA Approval Of CT-P41, Biosimilar Of Prolia® / Xgeva®

On November 30, 2023, Celltrion announced that it filed for an abbreviated Biologics License Application (aBLA) for FDA approval of CT-P41 (denosumab), a proposed biosimilar of Amgen's Prolia^® / Xgeva^® (denosumab). There is currently another pending aBLA for a proposed biosimilar of Prolia^® / Xgeva^® from Sandoz for GP2411, which was accepted by the FDA in February 2023. A litigation involving GP2411 was filed in May 2023 and is currently pending. Amgen, Inc. et al v. Sandoz, Inc. et al, No. 1:23-cv-02406 (D.N.J.). No patent disputes related to Celltrion's CT-P41 have been filed yet.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Monica Chou
Venable LLP
Rockefeller Center, 1270 6th Ave
New York
NY 10020
UNITED STATES
URL: www.Venable.com

© Mondaq Ltd, 2024 - Tel. [phone] - http://www.mondaq.com, source Business Briefing